Young patients with lung cancer have unique clinicopathological and gene mutation characteristics, such as common in women, no smoking history, mainly adenocarcinoma, with advanced TNM stage, and prevalence of targeted genetic alterations such as ALK gene and EGFR gene mutations. This evidence concerns the gene ALK and lung cancer.